Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MIF | P14174 | 5/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.43 |
| ▸ | F2R | P25116 | 3/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 5/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 3/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | DUSP3 | P51452 | 1/20 | 0.40 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9447682 | 0.93 | MIF (0.48) | MIFALDH1A1F2RMAPK1MEN1 | |
| SCHEMBL17165027 | 0.83 | ALDH1A1 (0.41) | MIFALDH1A1F2RMAPK1MEN1 | |
| SCHEMBL11132050 | 0.81 | F2R (0.51) | ALDH1A1F2RMAPK1MEN1KMT2A | |
| SCHEMBL18421326 | 0.78 | MIF (0.50) | MIFALDH1A1MAPK1MEN1KMT2A | |
| SCHEMBL11385092 | 0.76 | CYP19A1 (0.51) | ALDH1A1F2RMAPK1MEN1KMT2A | |
| SCHEMBL17156136 | 0.76 | MIF (0.72) | MIFALDH1A1MAPK1MEN1KMT2A | |
| SCHEMBL17156221 | 0.76 | MIF (0.68) | MIFALDH1A1MAPK1MAPTPOLB | |
| SCHEMBL9694360 | 0.74 | F2R (0.43) | ALDH1A1F2RMAPK1MEN1KMT2A | |
| SCHEMBL20237367 | 0.73 | MIF (0.46) | MIFALDH1A1MAPK1MEN1KMT2A | |
| SCHEMBL17261583 | 0.73 | MIF (0.72) | MIFALDH1A1MAPK1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10160732-B2 | MIF inhibitors | MIFCARE (FR) | 2018-12-25 | — | — | US | claimed |
| EP-2929882-B1 | MIF inhibitors | MIFCARE (FR) | 2018-06-13 | — | — | EP | claimed |
| US-20170029387-A1 | MIF INHIBITORS | APAXEN (BE) | 2017-02-02 | — | — | US | claimed |
| WO-2015155358-A1 | MIF INHIBITORS | MIFCARE (FR) | 2015-10-15 | — | — | WO | claimed |
| US-10160732-B2 | MIF inhibitors | MIFCARE (FR) | 2018-12-25 | — | — | US | disclosed |
| EP-2929882-B1 | MIF inhibitors | MIFCARE (FR) | 2018-06-13 | — | — | EP | disclosed |
| US-20170029387-A1 | MIF INHIBITORS | APAXEN (BE) | 2017-02-02 | — | — | US | disclosed |
| WO-2015155358-A1 | MIF INHIBITORS | MIFCARE (FR) | 2015-10-15 | — | — | WO | disclosed |
| US-8003297-B2 | Polymeric material, containing a latent acid | BASF SE (DE) | 2011-08-23 | — | — | US | disclosed |
| US-20100093950-A1 | POLYMERIC MATERIAL, CONTAINING A LATENT ACID | CIBA CORPORATION | 2010-04-15 | — | — | US | disclosed |
| US-7655380-B2 | Polymeric material, containing a latent acid | CIBA SPECIALTY CHEMICALS CORPORATION (US) | 2010-02-02 | — | — | US | disclosed |
| US-20090155716-A1 | Polymeric material containing a latent acid, i.e. a compound which is not an acid but which can be converted to an acid by the influence of laser irradiation | HENEGHAN MICHAEL | 2009-06-18 | — | — | US | disclosed |
| EP-1407322-B1 | LASER MARKING METHOD | CIBA HOLDING INC (CH) | 2008-12-17 | — | — | EP | disclosed |
| US-7264916-B2 | Laser marking method | CIBA SPECIALTY CHEMICALS CORPORATION (US) | 2007-09-04 | — | — | US | disclosed |
| US-7198884-B2 | Heat stable photocurable resin composition for dry film resist | CIBA SPECIALTY CHEMICALS CORP. (US) | 2007-04-03 | — | — | US | disclosed |
| US-7198884-B2 | Heat stable photocurable resin composition for dry film resist | CIBA SPECIALTY CHEMICALS CORP. (US) | 2007-04-03 | — | — | US | disclosed |
| US-20070054220-A1 | Polymeric material, containing a latent acid | HENEGHAN MICHAEL | 2007-03-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10160732-B2 | MIF inhibitors | MIF, MSR1, MMP12 | MIF 1/4885ALDH1A1 886/4885F2R 297/4885 |
| US-20170029387-A1 | MIF INHIBITORS | MIF, MSR1, MMP12 | MIF 1/4885ALDH1A1 886/4885F2R 297/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.